Supplementary Table S8 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
Year: 2025
Type: supplementary-materials
Abstract: Supplemental Table 8: PD-L1 Expression (MEL score*) and Clinical Response (iRECIST) in Patients with Metastatic Cutaneous Melanoma
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408094123